MetaCap

Enveric Biosciences (ENVB) vs Longeveron (LGVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enveric Biosciences is the larger company by market cap ($6.0 million vs $5.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENVB-9.70%LGVN-31.97%
+39%-4%-47%
Oct 7, 20261 yearNov 20, 2026
ENVB-6.90%LGVN-33.06%
+7%-20%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENVB versus LGVN key metrics
MetricENVBLGVN
Share price$1.35$1.66
Market cap$6.04M$5.60M
1-day change-4.26%-8.79%
EPS (TTM)$-13.01$-7.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.20M
Revenue growth (YoY)—-49.87%
Net income (latest FY)$-8.77M$-22.70M
Gross margin—66.97%
Operating margin—-1942.20%
Net margin—-1893.58%
52-week high$13.25$12.30
52-week low$1.17$1.31
Distance from 52-week high-89.81%-86.50%
Analyst consensus—none
Avg. price target upside—+3589.76%
Average volume56.55K115.35K
Shares outstanding4.48M3.23M
Employees538
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enveric Biosciences

ENVB stock →

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

ENVB vs LGVN FAQ

Which is bigger, Enveric Biosciences or Longeveron?

Enveric Biosciences (ENVB) is larger, with a market capitalization of $6.04M compared with $5.60M for Longeveron (LGVN).

Are Enveric Biosciences and Longeveron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons